BioNTech und Mitgründer kündigen Pläne für neues Mitgründer-geführtes Unternehmen zur Entwicklung von mRNA-Innovationen der nächsten Generation an, während BioNTech auf dem Weg zu einem Multi-Produkt-Unternehmen bis 2030 voranschreitet
View original at globenewswire.comBioNTech und Mitgründer kündigen Pläne für neues Mitgründer-geführtes Unternehmen zur Entwicklung von mRNA-Innovationen der nächsten Generation an, während BioNTech auf dem Weg zu einem Multi-Produkt-Unternehmen bis 2030 voranschreitet BioNTech stärkt strategische Ausrichtung auf die wachsende spätklinische Pipeline mi…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
This plan can offer significant added value for both BioNTech and the new company, as it opens opportunities for both organizations to make meaningful contributions to patient benefit
60% confidenceVision has always been to translate science into progress for patients
60% confidenceBioNTech expects to have 15 ongoing Phase 3 oncology trials by end of 2026
60% confidenceBioNTech expects to maximize value for patients and shareholders through these plans
60% confidence2026 will be the first year the company expects multiple late-phase clinical trial data updates in various high-incidence cancer indications
60% confidenceBinding agreement expected to be signed by end of first half of 2026
60% confidenceNow is the right time to prepare the handover of the baton
60% confidenceBioNTech is now very well positioned to continue its mission and establish itself as a commercial biopharma company with multiple approved products
60% confidence
Data points we hold from this source
| BioNTech SE · company age | 18 years |